title: Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
authors.forename: Peter Q
authors.initials: PQ
authors.lastname: Eichacker
authors.forename: Robert L
authors.initials: RL
authors.lastname: Danner
authors.forename: Anthony F
authors.initials: AF
authors.lastname: Suffredini
authors.forename: Xizhong
authors.initials: X
authors.lastname: Cui
authors.forename: Charles
authors.initials: C
authors.lastname: Natanson
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011486:Protein C / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated